Accueil   Diary - News   All news Erytech announces continuation of its phase 2B study

Erytech announces continuation of its phase 2B study

ERYTECH, the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs,announces that an independent Data and Safety Monitoring Board (DSMB[1]) completed its third safety assessment of the company’s Phase 2b ENFORCE 1 study in acute myeloid leukemia (AML) and that enrollment will continue until completion.

 

Read the press release